NCT06049901

Nitazoxanide in Patients With Metastatic Colorectal Cancer

Name: Clinical Trial NCT06049901
Creator: Tanta University
Keywords: Metastatic Colorectal Cancer, Nitazoxanide, Phase 3, drug, clinical trial, Egypt

Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Patients With Metastatic Colorectal Cancer

Tanta University·Phase 3·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Metastatic Colorectal Cancer
Drug/Device/Intervention: Nitazoxanide
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Tanta University
Location: Tanta, Egypt

Timeline & enrollment

Phase: Phase 3
Start date: Mar 01, 2023
End date: Mar 01, 2026
Enrollment: 60 participants

Primary outcome

Investigating the possible efficacy of nitazoxanide through evaluation of its impact on overall response rate (ORR) and disease control rate (DCR).,Evaluating the change in the serum level of Reduced glutathione (GSH),Evaluating the change in the serum level of Superoxide dismutase (SOD),Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB),Evaluating the change in the serum level of Protein disulfide isomerase (PDI)

Summary

The aim of this study is to evaluate the potential efficacy and safety of nitazoxanide in patients with metastatic colorectal cancer.

ICD-10 classifications

Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06049901
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06049901 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.